{
  "id": 17552930,
  "title": "Actuate Therapeutics CEO Daniel Schmitt purchases $49,999 in stock",
  "url": "https://urgent.news/2026/11/01/actuate-therapeutics-ceo-daniel-schmitt-purchases-49-999-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-01T06:31:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/actuate-therapeutics-ceo-daniel-schmitt-purchases-49999-in-stock-93CH-4989402"
  },
  "original_language": "en",
  "account": "Actuate Therapeutics CEO Daniel Schmitt purchased 140,844 shares of the company's common stock for a total of $49,999 on October 28, 2026. The shares were bought at $0.355 per share, placing the transaction during a period when the stock price was near its 52-week low of $0.33. Schmitt's acquisition of 140,844 shares came alongside the issuance of 70,422 detachable warrants to purchase additional common stock, which will expire on October 28, 2031. These warrants, issued as part of the public offering, were each valued at $0.45 per share and came without additional consideration. Following the stock market's recent performance and regulatory updates, H.C. Wainwright maintained its Buy rating on Actuate Therapeutics, setting a price target of $15.00. The company recently reported its second-quarter 2026 results, with FDA clearance granted for a Phase 1/2 study of its oral drug, elraglusib. This development, combined with the recent support from H.C. Wainwright, signals confidence in Actuate Therapeutics' future prospects as it advances elraglusib through clinical trials.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}